Bupropion

Bupropion, dem formerly call amfebutamone, wey na dem sell am under de brand name Wellbutrin among odas, be an atypical antidepressant wey na dem indicate am insyd de treatment of major depressive disorder den seasonal affective disorder den to support smoking cessation. A norepinephrine–dopamine reuptake inhibitor (NDRI), e sanso be popular as an add-on medication insyd de cases of "incomplete response" to de first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion get chaw features wey dey distinguish am from oda antidepressants: E usually no dey cause sexual dysfunction, e no be associated plus weight gain den sleepiness, wey e be more effective dan SSRIs at improving symptoms of hypersomnia den fatigue. Bupropion, particularly de immediate-release formulation, dey carry a higher risk of seizure dan chaw oda antidepressants; hence, caution be recommended insyd patients plus a history of seizure disorder. Dem dey take de medication by mouth.

Common adverse effects of bupropion plus de greatest difference from placebo be dry mouth, nausea, constipation, insomnia, anxiety, tremor, den excessive sweating. Raised blood pressure be notable. Rare buh serious side effects dey include seizures, liver toxicity, psychosis, den risk of overdose. Bupropion use during pregnancy fi be associated plus increased likelihood of congenital heart defects.

Bupropion dey act as a norepinephrine–dopamine reuptake inhibitor (NDRI) den a nicotinic receptor antagonist. However, ein effects on dopamine be weak den clinical significance be contentious. Chemically, bupropion be an aminoketone wey dey belong to de class of substituted cathinones den more generally dat of substituted amphetamines den substituted phenethylamines.

Na Nariman Mehta, wey work at Burroughs Wellcome, insyd 1969 invent bupropion. Na dem first approve am for medical use insyd de United States insyd 1985. Na dem originally call Bupropion by de generic name amfebutamone, before na dem rename am insyd 2000. Insyd 2023, na e be de seventeenth most commonly prescribed medication insyd de United States den de third most common antidepressant, plus more dan 30million prescriptions. E be on de World Health Organization's List of Essential Medicines. Insyd 2022, na de US Food and Drug Administration (FDA) approve de combination dextromethorphan/bupropion to serve as a rapid-acting antidepressant insyd patients plus major depressive disorder.

 References 

 External links 

Category:3-Chlorophenyl compounds
Category:5-HT3 receptor negative allosteric modulators
Category:Anorectics
Category:Antidepressants
Category:Anti-obesity drugs
Category:Aphrodisiacs
Category:Attention deficit hyperactivity disorder management
Category:Cathinones
Category:CYP2D6 inhibitors
Category:Dermatoxins
Category:Drugs wey GSK plc develop
Category:Ergogenic aids
Category:Female sexual dysfunction drugs
Category:Nicotinic antagonists
Category:Norepinephrine–dopamine reuptake inhibitors
Category:Pro-motivational agents
Category:Prodrugs
Category:Sigma receptor modulators
Category:Smoking cessation
Category:Stimulants
Category:Tert-butyl compounds
Category:Wakefulness-promoting agents
Category:World Health Organization essential medicines
Category:Translated from MDWiki